ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1425

Sjögren’s Syndrome and Interstitial Lung Disease: Experience in a Collaborative Rheumatology-Pulmonology Clinic

Sonia Jiménez Barrios1, Sandra Garrote Corral2, Juan Rigual3, Carlos de La Puente Bujidos3, Maria Angeles Blazquez Canamero4 and Jesús Loarce3, 1Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, 2Hospital Universitario Ramón y Cajal, Madrid, Spain, 3Ramón y Cajal University Hospital, Madrid, Madrid, Spain, 4Hospital Ramon y Cajal, Madrid, Madrid, Spain

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, interstitial lung disease, pulmonary, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Sjögren's Syndrome – Basic & Clinical Science Poster I

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Pulmonary lung disease represents the most prevalent extra-glandular manifestation in patients with Sjögren’s syndrome (SS). Notably, interstitial lung disease (ILD) stands out as the most severe pulmonary complication. Recent studies show a pooled SS–ILD prevalence of around 23%. Research on ILD and SS is limited, and there is a lack of information regarding the proportion of patients who experience progressive pulmonary fibrosis (PPF) during follow-up.

Methods: A descriptive and prospective study was performed using a cohort of patients with SS and ILD collected from a collaborative Rheumatology-Pulmonology clinic. Patients who met the 2016 ACR/EULAR criteria for SS and had a diagnosis of ILD on computed tomography (CT) were recruited prospectively. Sociodemographic and clinical data were collected. During follow-up, dyspnea progression, pulmonary function test (forced vital capacity [FVC], diffusion capacity for carbon monoxide [DLCO]), and computed tomography findings were monitored. Progressive pulmonary fibrosis (PPF) was defined according to the ATS/ERS/JRS/ALAT criteria.

Results: A total of 32 subjects diagnosed with SS-ILD were included. Demographics and baseline characteristics are shown in Table 1. The mean follow-up time in the collaborative clinic was 18.2 months. Most patients had non-specific interstitial pneumonia (NSIP) or lymphoid interstitial pneumonia (LIP) patterns, and approximately one-third had concomitant airway involvement. The different patterns of involvement and their progression are presented in Table 2.

Extrapulmonary manifestations were common in this cohort. The most frequent manifestations were Raynaud’s phenomenon (18.8%), peripheral nervous system involvement (9.4%), and arthritis (9.4%). A total of 6 patients (18.8%) had concomitant neoplasia, half of which were hematologic.

Half of the patients were receiving corticosteroid therapy at the baseline visit. The most frequent immunosuppressive therapies were azathioprine (21,9%) and rituximab (21,9%), followed by methotrexate (15.6%) and mycophenolate (12.5%). Additionally, one patient received tocilizumab (3.1%).

During the follow-up, only three patients met the criteria for PPF. Two of these patients had a fibrotic NSIP pattern, while the third presented a usual interstitial pneumonia (UIP) pattern. Only two patients received treatment with nintedanib, with one requiring discontinuation due to adverse effects (diarrhea and weight loss). There were no hospitalizations for acute exacerbations or deaths.

Conclusion: In our cohort of patients with SS and ILD, the majority demonstrated functional and radiological stability during follow-up. Only 9.4% of the patients met the criteria for PPF, and there were no acute exacerbations or deaths. However, larger cohorts and longer follow-ups are needed to confirm these findings.

Supporting image 1

Table 1. Patient demographics and baseline characteristics.

Supporting image 2

Table 2. ILD characteristics and disease progression. UIP = Usual interstitial pneumonia, NSIP = Nonspecific interstitial pneumonia, LIP = Lymphoid interstitial pneumonia, OP = Organizing pneumonia.


Disclosures: S. Jiménez Barrios: None; S. Garrote Corral: None; J. Rigual: None; C. de La Puente Bujidos: None; M. Blazquez Canamero: None; J. Loarce: None.

To cite this abstract in AMA style:

Jiménez Barrios S, Garrote Corral S, Rigual J, de La Puente Bujidos C, Blazquez Canamero M, Loarce J. Sjögren’s Syndrome and Interstitial Lung Disease: Experience in a Collaborative Rheumatology-Pulmonology Clinic [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/sjogrens-syndrome-and-interstitial-lung-disease-experience-in-a-collaborative-rheumatology-pulmonology-clinic/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sjogrens-syndrome-and-interstitial-lung-disease-experience-in-a-collaborative-rheumatology-pulmonology-clinic/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology